ArticleFrontiers in medicine2025
Comparative study of eGFR in cancer and non-cancer individuals: a multicenter analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is the second leading cause of death worldwide, and renal impairment frequently occurs during its course and treatment due to nephrotoxic chemotherapy and contrast exposure. Understanding baseline estimated glomerular filtration rate (eGFR) and its longitudinal changes in cancer patients is essential for effective kidney function management. Methods: This multicenter study included 24,478 treatment-naïve cancer patients admitted to three cancer centers in 2018 and 61,883 non-cancer individuals undergoing health screening in the same year, with follow-up until 2023. eGFR was calculated using the CKD-EPI equation. Baseline eGFR and subsequent changes were compared between groups after stratification by age, sex, and comorbidity. Results: Across all age groups, treatment-naïve cancer patients showed higher baseline eGFR values compared with non-cancer individuals of the same stratum (all Conclusion: Treatment-naïve cancer patients exhibited higher baseline eGFR but a more pronounced subsequent decline compared with non-cancer individuals. These findings reflect observed associations rather than causal effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.